| Pack Size | Single Vial, 10-Pack |
|---|
Cagrilintide (AM833) is a long-acting synthetic analogue of the pancreatic hormone amylin, engineered as a 37-amino-acid peptide that acts as a dual agonist at the amylin and calcitonin receptors. A fatty-diacid acylation extends its plasma half-life to roughly one week, supporting once-weekly subcutaneous dosing in research protocols. Investigators have examined the compound as a standalone weight-management agent in a dose-finding Phase 2 trial (PMID 34798060) and in combination with semaglutide, the pairing known in the literature as the cagrilintide-and-semaglutide combination (PMID 33894838, PMID 37364590). Each batch carries a Janoshik Analytical Certificate of Analysis covering HPLC purity quantification and MS identity confirmation, with a minimum-acceptance threshold of 99 percent purity by HPLC. Supplied as a lyophilized powder in a sealed glass vial, 10 mg per vial. Research-grade laboratory compound; human and veterinary use are excluded.
Description
Cagrilintide is a 37-residue synthetic peptide built on the backbone of human amylin (islet amyloid polypeptide), the hormone co-secreted with insulin from pancreatic beta cells. The design borrows the solubility-stabilising strategy of pramlintide — the first-generation amylin analogue — and adds modifications that extend duration of action. Key residue substitutions (including at positions 14, 17, and 37) improve physical stability and receptor pharmacology, while the native intramolecular disulfide bridge between the two N-terminal cysteines is retained. The defining modification is an N-terminal acylation with a C20 eicosanedioic fatty diacid attached through a gamma-glutamic acid linker. This acyl chain binds reversibly to circulating albumin, slowing clearance and pushing the elimination half-life to approximately 159–195 hours.
That pharmacokinetic profile supports once-weekly subcutaneous dosing in research protocols, in contrast to native amylin and to pramlintide, both of which are cleared far too quickly for weekly administration. Cagrilintide carries the development identifiers AM833 and NN0174-0833.
Researchers have studied the compound along two lines. As a standalone agent, a multicentre dose-finding Phase 2 trial evaluated once-weekly cagrilintide across a 0.3–4.5 mg dose range in adults with overweight or obesity, with a liraglutide 3.0 mg active-comparator arm (PMID 34798060). As a combination agent, the compound has been co-administered with the GLP-1 receptor agonist semaglutide — the fixed pairing — first in a Phase 1b safety and pharmacokinetics study (PMID 33894838) and subsequently in a Phase 2 trial in type 2 diabetes (PMID 37364590) and later Phase 3 work (PMID 40544432).
Ronin Peptides supplies cagrilintide as a research-grade lyophilized peptide for laboratory use only. It is sold strictly for benchwork and is not a pharmaceutical formulation.
Mechanism in research literature
Cagrilintide is a non-selective agonist of the amylin-receptor family and the calcitonin receptor. The amylin receptors (designated AMY1R, AMY2R, and AMY3R) are heterodimers formed by the calcitonin receptor core paired with one of three receptor-activity-modifying proteins (RAMP1, RAMP2, RAMP3); cagrilintide activates these receptors as well as the calcitonin receptor itself. The principal sites of action described in the amylin literature are the area postrema in the brainstem and appetite-regulating regions of the hypothalamus, where receptor engagement is associated with increased satiety, reduced food intake, and slowed gastric emptying (PMID 40332747).
The amylin pathway is mechanistically distinct from — and complementary to — the GLP-1 pathway targeted by compounds such as semaglutide. This complementarity is the rationale behind the cagrilintide-and-semaglutide combination: amylin-receptor agonism and GLP-1-receptor agonism engage separate central and peripheral circuits that both converge on reduced energy intake, and researchers have examined whether co-administration produces additive effects on body weight and glycemic endpoints (PMID 33894838, PMID 37364590).
Pharmacokinetic engineering underlies the compound's long duration of action. Native amylin is cleared within minutes; cagrilintide's C20 fatty-diacid acylation binds reversibly to serum albumin, holding the peptide in circulation and extending the elimination half-life into the 159–195 hour range. The combination of stabilising residue substitutions and albumin-mediated retention is what converts a short-lived native hormone into a candidate for once-weekly research dosing.
Studied properties
Body-weight reduction as a standalone agent is the original research stream for the compound. The dose-finding Phase 2 trial (PMID 34798060) randomised adults with overweight or obesity to once-weekly cagrilintide across a 0.3–4.5 mg dose range, to a liraglutide 3.0 mg active comparator, or to placebo, over 26 weeks. Researchers reported dose-dependent mean body-weight reductions rising to approximately 10.8 percent at the 4.5 mg dose tier, compared with roughly 3.0 percent on placebo and 8.6 percent on the liraglutide comparator — establishing amylin-receptor agonism as a body-weight research target in its own right.
Combination with semaglutide is the second and now larger research stream. The Phase 1b study (PMID 33894838) evaluated concomitant administration of multiple ascending doses of cagrilintide with semaglutide 2.4 mg, characterising the safety, tolerability, and pharmacokinetics of the pairing and reporting no unexpected interaction that would preclude combined development. The Phase 2 trial in type 2 diabetes (PMID 37364590) compared co-administered once-weekly cagrilintide 2.4 mg plus semaglutide 2.4 mg against semaglutide alone, examining glycemic and body-weight endpoints.
Later-stage combination research has extended into Phase 3. A 2025 trial reported outcomes for cagrilintide–semaglutide in adults with overweight or obesity and type 2 diabetes (PMID 40544432), adding to the evidence base characterising the combined amylin/GLP-1 approach.
The broader amylin mechanism — mode of action, receptor pharmacology, and translational potential across diabetes and obesity research — is summarised in a 2025 review (PMID 40332747), which situates cagrilintide within the wider amylin-analogue landscape alongside pramlintide.
The properties above describe the published research landscape and are provided for scientific context only. They are not claims of efficacy. Ronin Peptides supplies the compound exclusively as a research-grade reagent and provides no dosing protocols or therapeutic recommendations.
Compound specifications
| Specification | Value |
|---|---|
| Common name | Cagrilintide |
| Schema alternate name | Cagrilintide Acetate; AM833; NN0174-0833 |
| Class | Synthetic 37-amino-acid long-acting amylin analogue (dual amylin / calcitonin receptor agonist) |
| Length | 37 amino acids |
| Molecular formula | C194H312N54O59S2 |
| Molecular weight | ~4409 g/mol (free peptide) |
| CAS number | 1415456-99-3 |
| Backbone modifications | Pramlintide-like residue substitutions (incl. positions 14, 17, 37); retained N-terminal disulfide bridge; N-terminal γ-Glu-linked C20 eicosanedioic fatty-diacid acylation (albumin binding) |
| Receptor target | Amylin receptors (AMY1R/AMY2R/AMY3R; calcitonin-receptor + RAMP heterodimers) and the calcitonin receptor; area postrema and hypothalamus |
| Plasma half-life | ~159–195 hours (~1 week, subcutaneous) |
| Form | Lyophilized white-to-off-white powder |
| Solubility | Bacteriostatic water; sterile water for injection |
| Vial contents | 10 mg peptide, sealed amber-glass vial under inert gas |
| Purity | ≥99% by HPLC (verified per batch by Janoshik Analytical) |
Storage and handling
Unopened lyophilized vials hold up well under dry ambient conditions, with usable activity persisting for several weeks even without refrigeration. The unopened original vial is the recommended container until the moment of reconstitution. Refrigeration at 2–8 °C extends practical shelf life into months. Long-term archival storage uses −20 °C in a standard laboratory or household freezer.
Keep vials shielded from light, ideally in their original outer packaging. The fatty-acid acylation introduces an oxidation-sensitive feature, so light protection matters more here than for unmodified peptide chains.
After reconstitution, refrigerate the solution at 2–8 °C without delay. Working potency for a reconstituted preparation is typically four to six weeks under refrigeration — somewhat shorter than the upper end seen with smaller, simpler peptides, since acylated analogues are more sensitive than basic peptide chains.
When a research timeline extends past the working window, common practice is splitting the reconstituted solution into single-use volumes immediately after reconstitution and freezing those aliquots at −20 °C. Each freeze–thaw cycle damages peptide chains, and pre-splitting eliminates the cumulative loss that comes from thawing one bulk vial repeatedly. Thaw individual aliquots overnight in a refrigerator and use within a few days.
The reconstitution diluent is USP-grade bacteriostatic water containing 0.9% benzyl alcohol; see the bacteriostatic water product page for reconstitution-grade water.
Compare with similar compounds
| Compound | Class | Documented mechanism (clinical research) | Format at Ronin |
|---|---|---|---|
| Cagrilintide | Long-acting amylin analogue (dual amylin / calcitonin receptor agonist) | Amylin-pathway agonism in area postrema and hypothalamus; increased satiety, reduced food intake, slowed gastric emptying | 10 mg vial |
| Semaglutide | GLP-1 receptor mono-agonist | Glucose-dependent insulin release, glucagon suppression, gastric-emptying delay, central appetite modulation | 10 mg vial |
| Tirzepatide | Dual GLP-1 / GIP receptor agonist | Two-incretin-receptor agonism; adds GIP-mediated insulin and adipose effects to the GLP-1 baseline | 10 mg vial |
Cagrilintide occupies a mechanistic neighbourhood distinct from the GLP-1-class incretin peptides. Rather than incrementing receptor coverage within the incretin family (as the Semaglutide → Tirzepatide progression does), it engages an entirely separate hormonal axis — amylin. That separation is precisely why it is studied alongside semaglutide as the cagrilintide-and-semaglutide combination: the two compounds act through different receptors that converge on reduced energy intake, and the combination research examines whether the effects stack (PMID 37364590).
Reconstitution and laboratory handling
A 10 mg cagrilintide vial reconstituted with 2 mL of bacteriostatic water yields a working concentration of 5 mg/mL. Alternative dilutions: 1 mL gives 10 mg/mL (concentrated stock); 4 mL gives 2.5 mg/mL (dilute stock).
Reconstitution procedure:
- Bring both vials — peptide and bacteriostatic water — to room temperature before opening.
- Sanitise both rubber stoppers with an alcohol swab.
- Pull the chosen diluent volume into a sterile transfer syringe.
- Direct the water down the inner wall of the peptide vial as it goes in — never onto the lyophilized cake itself, which would foam and damage peptide structure at the air-water interface.
- Invert slowly or swirl gently until everything dissolves. Do not vortex; do not shake.
- Refrigerate at 2–8 °C the moment reconstitution completes.
A finished preparation should be visually transparent. If hazy, treat as degraded or contaminated and discard.
For concentration math across different reconstitution volumes, the Ronin peptide reconstitution calculator handles the mg-to-mL conversions.
Frequently asked questions
What is Cagrilintide?
Cagrilintide (AM833) is a 37-amino-acid synthetic analogue of the hormone amylin, engineered as a long-acting dual agonist at the amylin and calcitonin receptors. An N-terminal fatty-diacid acylation binds circulating albumin and extends its half-life to roughly one week, enabling once-weekly subcutaneous dosing in research protocols. It has been studied as a standalone weight-management agent (PMID 34798060) and in combination with semaglutide (PMID 33894838, PMID 37364590). Ronin Peptides offers cagrilintide as a research-grade laboratory reagent, sold for bench use only and not intended for human or veterinary administration.
How does Cagrilintide differ from GLP-1 agonists like semaglutide?
They act through entirely different hormonal pathways. Semaglutide is a GLP-1 receptor agonist; cagrilintide is an amylin analogue that engages the amylin and calcitonin receptors, primarily in the area postrema and hypothalamus. Both pathways can reduce food intake, but through separate central and peripheral circuits. That mechanistic separation is the rationale for studying them together as the cagrilintide-and-semaglutide combination, where researchers examine whether amylin-pathway and GLP-1-pathway agonism produce additive effects (PMID 37364590).
What is the regulatory status of Cagrilintide?
Cagrilintide is a synthetic amylin analogue investigated for its effects on body weight and glycemic endpoints, both alone and combined with semaglutide. It is not listed as a scheduled controlled substance under the international drug-control conventions or the major national scheduling systems. It sits within the regulatory layer covering laboratory reagents and research chemicals, not the layer governing human therapeutics.
Ronin Peptides supplies the compound as a research-grade reagent for laboratory and bench-research applications. Buyers operate under their own jurisdictional laws and any applicable institutional review protocols when handling the compound — Ronin Peptides assumes no oversight of downstream lab practice.
How is Cagrilintide verified?
Each batch passes through Janoshik Analytical, an independent peptide-analytics lab, for HPLC purity quantification and MS identity confirmation, with the minimum acceptance threshold set at 99 percent purity by HPLC. Every Janoshik COA includes a verification key that resolves at janoshik.com, so researchers can confirm the certificate's authenticity without trusting the manufacturer's word alone. To pull the COA covering the batch on your order, email support@roninpeptides.ca with your order number; the typical reply turnaround is well under 24 hours.
How is Cagrilintide reconstituted?
The standard preparation is 2 mL of bacteriostatic water added to a 10 mg vial, producing a 5 mg/mL solution. Direct the water down the inner wall of the vial as it goes in — never onto the lyophilized cake itself. Swirl gently or invert slowly until fully dissolved. Refrigerate at 2–8 °C immediately after reconstitution. Use the Ronin reconstitution calculator for concentration math across different reconstitution volumes.
How do I receive the COA for my batch?
Email support@roninpeptides.ca from the email address used at checkout, with your order number (e.g., RP-CA-1234) and the compound name. We reply within 24 hours — typically the same business day — with the COA PDF attached. The COA includes the Janoshik verification key, which you can check independently at janoshik.com to confirm the test results match what the laboratory ran on your specific batch.
References
- Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021. PMID: 34798060
- Enebo LB et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021. PMID: 33894838
- Frías JP et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023. PMID: 37364590
- Davies MJ et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025. PMID: 40544432
- Volčanšek Š et al. Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity. Diabetes Ther. 2025. PMID: 40332747
